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Heterogeneous Nuclear Ribonucleoprotein K Supports Vesicular
Stomatitis Virus Replication by Regulating Cell Survival and Cellular
Gene Expression
Phat X. Dinh,a,b Anshuman Das,a,b Rodrigo Franco,a Asit K. Pattnaika,b
School of Veterinary Medicine and Biomedical Sciencesa and Nebraska Center for Virology,b University of Nebraska—Lincoln, Lincoln, Nebraska, USA

The heterogeneous nuclear ribonucleoprotein K (hnRNP K) is a member of the family of hnRNPs and was recently shown in a
genome-wide small interfering RNA (siRNA) screen to support vesicular stomatitis virus (VSV) growth. To decipher the role of
hnRNP K in VSV infection, we conducted studies which suggest that the protein is required for VSV spreading. Virus binding to
cells, entry, and nucleocapsid uncoating steps were not adversely affected in the absence of hnRNP K, whereas viral genome transcription and replication were reduced slightly. These results indicate that hnRNP K is likely involved in virus assembly and/or
release from infected cells. Further studies showed that hnRNP K suppresses apoptosis of virus-infected cells, resulting in increased cell survival during VSV infection. The increased survival of the infected cells was found to be due to the suppression of
proapoptotic proteins such as Bcl-XS and Bik in a cell-type-dependent manner. Additionally, depletion of hnRNP K resulted in
not only significantly increased levels of T-cell-restricted intracellular antigen 1 (TIA1) but also switching of the expression of
the two isoforms of the protein (TIA1a and TIA1b), both of which inhibited VSV replication. hnRNP K was also found to support expression of several cellular proteins known to be required for VSV infection. Overall, our studies demonstrate hnRNP K
to be a multifunctional protein that supports VSV infection via its role(s) in suppressing apoptosis of infected cells, inhibiting
the expression of antiviral proteins, and maintaining the expression of proteins required for the virus.

T

he K homology (KH) domain-containing subfamily of heterogeneous nuclear ribonucleoproteins (hnRNPs) has five
members, namely, the hnRNP K (the prototypic member of the
subfamily), the poly(C) binding protein 1 (PCBP1, also known as
hnRNP E1), PCBP2 (hnRNP E2), PCBP3, and PCBP4. All members of this subfamily carry three KH domains, which are responsible for binding to C- or U-rich regions in RNA and/or DNA (1).
These proteins, and in particular, hnRNP K, are known to participate in various cellular processes such as chromatin organization,
mRNA translation, regulation of transcription and splicing, RNA
shuttling, mRNA and/or protein stability, and cell survival (2, 3).
hnRNP K interacts with numerous cellular partners, including
oncogenic proteins such as tyrosine kinases (Lck and c-Src) (4)
and serine/threonine kinases (extracellular signal-regulated kinase/mitogen-activated protein kinase [ERK/MAPK]) (5), and
plays critical roles in cell growth, tissue development and differentiation including red blood cell differentiation (6), ovary development (7), and neuronal development (8). The observation that
hnRNP K is highly expressed in multiple cancerous tissues (9–12)
suggests its possible roles in cancer development and tumorigenesis. On the other hand, its sequestration, deficiency, or degradation marks the initial step for apoptotic progression (13–15).
hnRNP K has also been demonstrated to play key roles in many
viral infections. While interacting with the 5= untranslated region
(UTR), it supports replication of enterovirus 71 (16, 17); its interaction with the hepatitis B virus (HBV) genome leads to increased
viral DNA synthesis (18, 19). Dengue virus and herpes simplex
virus 1 (HSV-1) also have been shown to require the functions of
hnRNP K in progeny virus production (20, 21). hnRNP K not only
serves as a splicing factor for Tat/Rev exon 3 of HIV-1 (22) but also
interacts with viral components of Sindbis virus, chikungunya
virus, hepatitis C virus, African swine fever virus, human cyto-
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megalovirus (CMV), and Epstein-Barr virus (23–28) to support
virus growth.
Vesicular stomatitis virus (VSV) is an enveloped, nonsegmented, negative-stranded RNA virus in the Rhabdoviridae family
and replicates exclusively in the cytoplasm of infected cells. Recently, we demonstrated that PCBP2 and PCBP1 (PCBP1/2), two
members of the KH-domain-containing subfamily of hnRNPs,
inhibit VSV growth by negatively regulating viral gene expression
(29). Although the mechanism by which the PCBPs inhibit viral
gene expression and virus growth is unknown at this time, further
studies have revealed that the infected cells induce formation of
stress granule (SG)-like structures that contain not only PCBP2
but also other cellular RNA-binding proteins such as the T-cellrestricted intracellular antigen 1 (TIA1) and TIA1-related (TIAR)
proteins, which have been shown to inhibit VSV replication (30).
hnRNP K resides predominantly in the nucleus (31); however,
studies have shown that in VSV-infected cells, it is translocated
into the cytoplasm (32). The reason(s) for this altered subcellular
localization in infected cells is unclear, but it is possible that hnRNP K might be directly or indirectly involved in VSV replication
and growth. This contention is further strengthened by the identification of hnRNP K as one of the host factors required for VSV
infection in a genome-wide small interfering RNA (siRNA) screen
(33). Since both PCBP2 and hnRNP K proteins are in the same
subfamily with similar domain organizations and functions, it is
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surprising to observe opposite effects of these two proteins on
VSV infection. In this communication, we conducted studies to
examine the role of hnRNP K in supporting VSV infection. Our
studies show that hnRNP K supports virus growth and infection
by enhancing the cell viability of infected cells. Further studies
reveal that the enhanced cell viability is due to increased levels of
several antiapoptotic factors such as Bcl-XL, Bcl-2, and Bag1
and/or decreased levels of proapoptotic factors such as Bcl-XS and
Bik in a cell-type-dependent manner. In addition, our studies reveal that hnRNP K modulates expression of certain cellular proteins that have been found to be required for VSV replication,
while also downregulating expression of certain cellular proteins
previously shown to inhibit virus replication. The key findings
reported here suggest that hnRNP K supports VSV growth by
prolonging survival of the virus-infected cells and modulating expression of cellular factors influencing virus growth.
MATERIALS AND METHODS
Cell culture and reagents. Monolayer cultures of HeLa (ATCC CCL2),
HEK293, Huh7, and MCF-7 cells were maintained in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 8% fetal bovine serum
(FBS) and the antibiotics penicillin (100 units/ml), kanamycin (20 units/
ml), and streptomycin (20 units/ml) (PKS). Baby hamster kidney (BHK21) cells were maintained in minimal essential medium (MEM) supplemented with 5% fetal bovine serum (FBS) and the antibiotics (PKS).
Immortalized murine embryonic fibroblasts (MEFs) from wild-type (wt)
and TIA1-knockout mice (34) were obtained from P. Anderson (Harvard
University) and were maintained as described previously (30).
Viruses and VSV RNP or nucleocapsid (NC) preparation. Stocks of
wt VSV, VSV expressing enhanced green fluorescent protein (eGFP) and
eGFP fused to the VSV phosphoprotein (VSV-eGFP and VSV-PeGFP,
respectively) were prepared as described earlier (35, 36). VSV⌬G (VSV
lacking the G protein) virus encoding PeGFP and VSV ribonucleocapsids
(RNPs) were prepared as previously described (29). VSV-PLuc was constructed by replacing the eGFP coding sequence in the VSV-PeGFP backbone (35) with the coding sequence of the luciferase (Luc) protein of
Renilla reniformis. First, the coding sequence of Renilla luciferase was
amplified from plasmid pRL-TK (Promega) by primers containing an
NotI site. After digestion with NotI, the fragment was inserted into a
VSV-PeGFP plasmid (35), which was digested with NotI to remove the
eGFP sequences. This resulted in the insertion of the entire coding sequences of luciferase in frame following amino acid 196 of the P protein.
Subsequently, VSV-PLuc was recovered according to a protocol described
previously (36).
Virus titration and infection. Virus titers were determined by plaque
assay on BHK-21 and HeLa cells. Virus infection in each experiment was
performed at a multiplicity of infection (MOI) of 1 or 0.01 PFU per cell,
except where indicated otherwise.
Antibodies. Anti-M (23H12) monoclonal antibodies were kindly provided by D. Lyles. Antibodies for actin (mouse monoclonal; sc-47778),
PCBP1 (goat polyclonal; sc-16504), PCBP2 (mouse monoclonal; sc101136), hnRNP K (mouse monoclonal; sc-28380), TIA1 (goat polyclonal; sc-1751), GS28 (rabbit polyclonal; sc-15270), NF90 (rabbit polyclonal; sc-22530), procaspase 3 (mouse monoclonal; sc-166589), alanine
deaminase-like (ADAL) (rabbit polyclonal; sc-138086), FLICE-inhibitory
protein (FLIP) (mouse monoclonal; sc-5276), Bad (mouse monoclonal;
sc-8044), Bak (rabbit polyclonal; sc-832), and Noxa (rabbit polyclonal;
sc-30209) were purchased from Santa Cruz Biotechnology, Inc. Antihemagglutinin (HA) monoclonal antibody HA-7 (H3663), goat anti-rabbit immunoglobulin (IgG)-horseradish peroxidase (A6154), goat
anti-mouse IgG-horseradish peroxidase (A4416), and rabbit anti-goat
IgG-horseradish peroxidase (A4174) were obtained from Sigma-Aldrich.
Antibody for cleaved caspase 3 (p17) (rabbit polyclonal; 9661) was purchased from Cell Signaling.
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Plasmid constructs. The plasmid encoding the full-length TIA1a
(variant 2, NM_022173.2) has been described before (30). TIA1b (variant
1, NM_022037.2) and hnRNP K (variant 1, NM_002140.3) were amplified from total RNA of HeLa cells using the specific primers shown in
Table 1. The PCR products were digested with KpnI and EcoRI and cloned
into pcDHA as described previously (29). These plasmids were named
pcDHA-TIA1b and pcDHA-hnRNP K. These constructs express the inserted gene with the HA epitope at the N terminus of the protein. Expression of the proteins can be driven by either a CMV promoter or T7 promoter located upstream of the coding sequences.
siRNA-mediated silencing. For depletion of PCBP1, PCBP2, TIA1,
and hnRNP K in HeLa, HEK293, Huh7, MCF-7, or BHK-21 cells, siRNAs
(pool of four different siRNAs) targeting PCBP1, PCBP2, TIA1 (catalog
numbers M-012243-01-0005, M-012002-01-0005, and L-013042-000005, respectively; Dharmacon), and hnRNP K (catalog numbers
J-011692-05, -06, -07, and -08, respectively, for duplexes 1, 2, 3, and 4;
Dharmacon) were transfected at a final concentration of 10 to 20 nM
(except where indicated otherwise), according to the protocol of reverse
transfection, with Lipofectamine RNAiMax (Invitrogen) as recommended by the manufacturer. At 24 h posttransfection (hpt), the transfection mix was replaced with DMEM containing 10% FBS and PKS, and
the cells were incubated further for 40 to 48 h to allow knockdown of the
gene. A nontargeting (NT) siRNA (catalog number 1027281; Qiagen)
which does not target any of the known mammalian genes was used as a
control siRNA.
Plasmid DNA and RNP (or NC) transfection. Transfection of plasmids was performed using Lipofectamine 2000 (Invitrogen) as per the
manufacturer’s instructions. At 4 hpt, the transfection mix was replaced
with complete growth medium and incubated for 40 to 44 h before being
used for assays. Transfection of viral RNPs was also performed using the
same procedure as used for plasmid transfection and as described previously (29).
WB. Western blotting (WB) and quantification of the protein bands
were performed as described before (29). Concentrations of antibodies
used were as follows: M, 1:1,000 to 1:3,000; actin, 1:3,000 to 1:5,000; procaspase 3 and PCBP2, 1:3,000; hnRNP K, 1:15,000; HA, 1:10,000; PCBP1,
TIA1, FLIP, Bad, Bak, and Noxa, 1:250 to 1:500 each; GS28, NF90, ADAL,
and cleaved caspase 3 (p17), 1:1,000 each. Secondary antibodies including
goat anti-rabbit immunoglobulin (IgG)-horseradish peroxidase, goat anti-mouse IgG-horseradish peroxidase, and rabbit anti-goat IgG-horseradish peroxidase were used at dilutions of 1:500 to 1:10,000.
qRT-PCR. The primers, probes, and the methods used for quantification of VSV P mRNA and antigenome RNA by quantitative real-time PCR
(qRT-PCR) were as described previously (33).
Semiquantitative RT-PCR. Total RNA from cells was extracted with
TRIzol (Invitrogen). First-strand cDNA was synthesized using total RNA
and oligo(dT) primer (Roche), followed by PCR amplification with specific primers (Table 1) to determine the mRNA levels of anti- and proapoptotic proteins. For an internal control, oligo(dT)-derived cDNA was
used to amplify ribosomal protein L32 (L32) mRNA using specific primers as described before (37). PCR cycling conditions used were 20 s at
94°C, 30 s at 54°C, and 30 s at 72°C for 28 to 40 cycles.
Cell viability assay and VSV entry assay based on luciferase activity.
A total of 2 ⫻ 104 HeLa cells/well were reverse transfected with 10 nM NT
or hnRNP K siRNA in opaque-walled, round-bottom, black 96-well plates
using Lipofectamine RNAiMax (Invitrogen). For cell viability assays, at 60
hpt, cells were washed with 1⫻ phosphate-buffered saline (PBS) and then
mock infected or infected with VSV-eGFP at an MOI of 0.1 in a volume of
40 l/well. After 1 h of incubation at 37°C, 60 l of complete medium was
added to each well, and the incubation continued for time points indicated in the figures. Cell viability was determined by directly adding 100 l
of CellTiter-Glo Reagent (Promega) to each well as per the manufacturer’s
instructions. Luciferase activity was recorded in a Veritas Microplate Luminometer (Turner Biosystems). For a VSV entry assay based on luciferase activity, at 60 hpt, the cells were infected with VSV-PLuc at an MOI of
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TABLE 1 Primers used in this study
Primer name

Primer sequence (5= to 3=)a

Purpose

TIA1-KpnI-F
TIA1-EcoRI-R
TIA1-KpnI-F
TIA1-spliced-R
hnRNPK-KpnI-F
hnRNPK-EcoRI-R
BclX-F
BclX-R
Bax-F
Bax-R
Bik-F
Bik-R
Bid-F
Bid-R
Mcl-1-F
Mcl-1-R
Bcl2-A1-F
Bcl2-A1-R
Bag1-F
Bag1-R
Bcl-2-F
Bcl-2-R
Bcl-W-F
Bcl-W-R
XIAP-F
XIAP-R

ATATGGTACCATGGAGGACGAGATGCCCAAG
ATATGAATTCTCACTGGGTTTCATACCCTGCC
ATATGGTACCATGGAGGACGAGATGCCCAAG
GATCACCAACAAAGACATGGAAATG
ATATGGTACCATGGAAACTGAACAGCCAG
ATATGAATTCTTAGAAAAACTTTCCAGAATACTG
CATATCAGAGCTTTGAACAG
TCATTTCCGACTGAAGAGTG
CAGCTCTGAGCAGATCATG
CACAGGGCCTTGAGCAC
TCTCCAGAGACATCTTGATG
GTTCGCAGGACACCCAG
TGGACCGTAGCATCCCTC
CAGTCCATCCCATTTCTGG
CGGGAGGGCGACTTTTG
GAACTCCACAAACCCATCC
CAGTGCGTCCTACAGATAC
GCCTTATCCATTCTCCTGTG
CAGCAATGAGAAGCACGAC
TGCAGAGAGCTTCAGCTTG
CGATAACCGGGAGATAGTG
CACCGTGGCAAAGCGTC
CTGGTGGCAGACTTTGTAG
CATCCACTCCTGCACTTG
TGGCACGAGCAGGGTTTC
CTCGGGTATATGGTGTCTG

Amplification and cloning of TIA1a and TIA1b

a

Differentiation of TIA1a from TIA1b
Amplification and cloning of hnRNP K
Differentiation of Bcl-XL from Bcl-XS
Amplification of Bax
Amplification of Bik
Amplification of Bid
Amplification of Mcl-1
Amplification of Bcl2-A1
Amplification of Bag1
Amplification of Bcl-2
Amplification of Bcl-W
Amplification of XIAP

Underlined sequences indicate restriction sites.

300 for 1 h on ice in a volume of 40 l/well, washed, and incubated at
37°C. At the time points indicated in the figures, luciferase assays were
performed by using a dual-luciferase assay kit (Promega).
Statistical analysis. Statistical analyses were performed using the
MIXED procedure of SAS (SAS Institute, Inc., Cary, NC). The statistical
model included “treatment” as a fixed effect. Data are presented as means ⫾
standard errors of means. A P value of ⬍0.05 was considered statistically
significant.

RESULTS

hnRNP K is required for VSV infection. In a previous highthroughput siRNA screening assay (33), we identified hnRNP K as
a cellular factor required for VSV infection. To understand further
the role of hnRNP K in VSV infection, we examined how depletion of hnRNP K affects virus growth in cultured HeLa cells.
Treating the cells with a pool of siRNAs specific for hnRNP K
resulted in a greater than 90% reduction in the levels of hnRNP K
compared to those seen in cells treated with a nontargeting (NT)
siRNA or in mock-treated cells (Fig. 1A). Infection of hnRNP
K-depleted cells with VSV resulted in a 5- to 6-fold reduction in
viral protein expression, as examined by monitoring the levels of
the viral M protein, compared to those in NT siRNA-transfected
cells (Fig. 1A and B). Evaluation of viral growth kinetics revealed
that the virus growth was significantly attenuated in cells depleted
of hnRNP K at all time points examined. At a low multiplicity of
infection (MOI of 0.01), the virus yield at 24 h postinfection (hpi)
was reduced over 15-fold in hnRNP K-depleted cells compared to
the yield from control NT siRNA-treated cells (Fig. 1C). A similar
difference in growth kinetics and virus yield was also observed
with the use of a higher MOI (1.0), and the overall virus yield was
diminished by about 5-fold (data not shown). The requirement of
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hnRNP K for VSV infection was also observed in MCF-7, Huh-7,
and HEK293 (data not shown) cells as well as in MEFs (see Fig. 4).
While depletion of hnRNP K resulted in significant inhibition of
VSV growth, ectopic expression of HA-tagged hnRNP K in cells
yielded reproducibly a 2-fold increase in viral protein expression,
as indicated by the M protein levels (Fig. 1D), and a similar 2-fold
increase in overall virus growth was observed (data not shown).
Taken together, the results from depletion and overexpression
studies suggest that hnRNP K is required for VSV growth and
infection.
The requirement for hnRNP K is primarily at the level of
virus propagation. To determine the step(s) at which hnRNP K is
required for VSV infection, we next examined the relative levels of
viral mRNA and full-length antigenomic RNAs synthesized in infected cells depleted of hnRNP K. In VSV infection at a low MOI
(0.01), we observed that the levels of M mRNAs and antigenomic
RNAs in hnRNP K-depleted cells were significantly decreased,
representing approximately 20% of those in NT siRNA-treated
cells (Fig. 2A). This was consistently seen in infected cells at early
(6 h) (data not shown) and late times (12 h) (Fig. 2A) postinfection. However, at a high MOI (1.0), the reduction in viral mRNA
and antigenomic RNA levels in hnRNP K-depleted cells was less
pronounced. The levels of these RNAs were about 70% of those
seen in NT siRNA-treated cells (Fig. 2B). The observations that
viral RNA synthesis was less affected by hnRNP K depletion at a
high MOI (a condition in which most of the cells in the culture
were infected) but that it was significantly reduced at a low MOI (a
condition in which majority of the cells in the culture were uninfected at early times of infection but could potentially be infected
with recently produced virions) suggest that although hnRNP K
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FIG 1 hnRNP K is required for VSV infection. (A) Suppression of VSV replication in cells depleted of hnRNP K. HeLa cells were transfected with 10 nM
siRNA for NT (lane 2) or 10 nM and 20 nM hnRNP K (siK) (lanes 3 and 4,
respectively) for 60 h. Cells were then infected with VSV at an MOI of 0.01 for
12 h. Equal amounts of cell lysates were analyzed by WB with anti-hnRNP K
and anti-M antibodies. Actin served as the loading control. (B) Quantification
of M protein levels (arbitrary units) from three independent experiments as
described in panel A with error bars representing the standard errors of means.
The level of M expression in the NT siRNA-treated sample was set at 1. ***,
P ⬍ 0.001. (C) Multicycle growth of VSV in cells depleted of hnRNP K. siRNA
(10 nM) treatment and virus infections were performed as described in panel
A; virus titers in supernatants collected at indicated time points were determined by plaque assay and are expressed as log10 PFU/ml. Statistical significance was determined for virus titers at 12, 18, and 24 hpi. ***, P ⬍ 0.001. (D)
VSV infection is enhanced in hnRNP K-overexpressing cells. HeLa cells transfected with 1.5 g of empty vector (EV) or an HA-hnRNP K (HA-K)-encoding
plasmid for 48 h were infected with VSV at an MOI of 0.01 for 12 h, and cell
lysates were analyzed by WB using anti-M or anti-HA antibodies. Actin served
as the loading control. ␣, anti; siK, siRNA targeting hnRNP K.

may play a role in viral gene expression to some extent, it likely
plays a more prominent role(s) at another step (or other steps) in
the virus replication cycle.
To further elucidate the role of hnRNP K in the VSV life cycle,
we investigated the requirement of hnRNP K at VSV entry/uncoating and assembly/budding steps. Transfection of VSV nucleocapsids (NCs) directly into cells bypasses the viral entry and uncoating steps, resulting in expression of the viral genes (29, 33).
Thus, we examined the effect of depletion of hnRNP K on viral
gene expression in cells transfected with the viral NCs. Results
show that NC transfection led to only a slight decrease (approximately 30%) in the levels of the viral M protein in cells treated with
siRNA for hnRNP K compared to levels in NT siRNA-transfected
cells (Fig. 2C, lanes 3 and 4). In contrast, an 8- to 10-fold reduction
in M protein levels was observed in cells infected at a low MOI
(0.01) with VSV (Fig. 2C, lanes 1 and 2). Infection of cells with
VSV⌬G virus (a virus that lacks the G gene and cannot produce
infectious particles, thereby limiting the infection with this virus,
which is incompetent in budding, to a single cycle only) also led to
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FIG 2 hnRNP K is required for VSV propagation. (A and B) VSV mRNA and
antigenomic RNA levels in cells depleted of hnRNP K and infected with the
virus at a low (0.01) or high (1.0) MOI (panels A and B, respectively) were
determined by qRT-PCR. Experimental conditions were as described in the
legend of Fig. 1A. Error bars represent the standard errors of means from three
independent experiments. ***, P ⬍ 0.001; *, P ⬍ 0.05. (C) hnRNP K is not
required for early stages of the VSV life cycle. HeLa cells were transfected with
10 nM siRNA for NT or targeting hnRNP K for 60 h. Cells were then treated as
follows: infected with VSV at an MOI of 0.01 for 12 h (lanes 1 and 2), supertransfected for 6 h with viral NC prepared from VSV (lanes 3 and 4), infected
with VSV⌬G at an MOI of 0.5 for 8 h (lanes 5 and 6), or infected with VSV at
an MOI of 1 for 4 h (lane 7 and 8). Cell lysates corresponding to equal amounts
of total proteins were analyzed by WB with anti-hnRNP K and anti-M antibodies. Actin served as the loading control. (D) HeLa cells were transfected
with siRNA as described in the legend of Fig. 1A. At 60 hpt, cells were infected
with VSV-PLuc at an MOI of 300. After 1 h of virus adsorption on ice, cells
were washed with PBS, and cell extracts at various times postincubation were
analyzed for luciferase activity. The luciferase activity in NT siRNA-treated
cells at various times postinfection was set at 1. Data show relative luciferase
activity and are expressed as the averages of three independent experiments,
with error bars representing the standard errors of means. NS, nonsignificant.
(E) HeLa cells were transfected with siRNA as described in the legend of Fig.
1A. At 60 hpt, cells were infected with VSV-PeGFP at an MOI of 0.05 or
VSV⌬G at an MOI of 0.5 for 12 h. The percentages of infected cells were
determined by counting the number of cells expressing green fluorescence
from PeGFP. Data show relative percent infection after normalizing the value
of cells treated with siRNA targeting hnRNP K to that of NT siRNA-treated
cells, which is set at 100, and are expressed as average of three independent
experiments with error bars representing the standards error of means. ***,
P ⬍ 0.001; NS, nonsignificant.

a slight decrease (approximately 30%) in the levels of the viral M
protein in hnRNP K siRNA-treated cells compared to the control
NT siRNA-treated cells (Fig. 2C, lanes 5 and 6). Furthermore,
using a high MOI (1.0) of VSV, we observed viral gene expression
at 4 hpi (a time at which viral gene expression is readily detectable

Journal of Virology

Requirement of hnRNP K in VSV Infection

FIG 3 hnRNP K regulates the expression of the two isoforms of TIA1 but not PCBP1/2. (A) Depletion of hnRNP K does not affect the expression of PCBP1/2.
HeLa cells were transfected with NT or hnRNP K siRNA at a concentration of 10 nM, and at 60 hpt, cells were infected with VSV at an MOI of 0.01 for 12 h. Cell
lysates were used for WB to detect the indicated proteins. (B to D) hnRNP K depletion results in increased levels of total TIA1 and the TIA1b isoform. HeLa cells
were mock transfected or transfected with NT or hnRNP K siRNA as a pool of four duplexes (pooled) or as individual duplexes (si DX1 to si DX4) at a
concentration of 10 nM, and at 60 hpt, the cells were infected with VSV at an MOI of 0.01 for 12 h. Cell lysates were used for WB to detect the indicated proteins
(B). Quantification of total TIA1 protein levels (arbitrary units) from three independent experiments is shown in panel C while the levels of TIA1a and TIA1b
isoforms are shown in panel D. The level of TIA1a expression in the NT siRNA-treated sample was set at 1. ***, P ⬍ 0.001; **, P ⬍ 0.01. (E) Switching of TIA1
isoform expression is regulated by hnRNP K protein at the mRNA level. The experiment was done as described in panel B. Total RNA was subjected to
semiquantitative RT-PCR to detect the two isoforms of TIA1. Ribosomal protein (RP) L32 mRNA served as an internal control. (F) Overexpression of TIA1a and
TIA1b inhibits VSV gene expression. HeLa cells transfected with 1.5 g of empty vector (EV) or HA-TIA1a- or HA-TIA1b-encoding plasmids for 48 h were
infected with VSV at an MOI of 0.1 for 12 h (lanes 1 to 3) or with VSV⌬G at an MOI of 0.5 for 8 h (lanes 4 to 6) or supertransfected for 6 h with viral NC prepared
from VSV (lanes 7 to 9), and cell lysates were analyzed by WB using anti-M or anti-HA antibodies. Actin served as the loading control. siPCBP1, siRNA targeting
PCBP1; siPCBP2, siRNA targeting PCBP2; siTIA1, siRNA targeting TIA1.

but virus assembly/budding is minimal) to be reduced by only
about 30% in cells treated with an siRNA for hnRNP K (Fig. 2C,
lanes 7 and 8) compared to that in NT siRNA-transfected cells.
These results show that bypassing entry/uncoating steps (NC
transfection), using assembly/budding-incompetent (VSV⌬G)
virus, or using high MOIs did not adversely affect overall viral
gene expression. On the other hand, a significant reduction in
viral gene expression under conditions of VSV infection at a low
MOI suggests that the supportive roles of hnRNP K in VSV infection are manifested when the infection undergoes multiple cycles,
indicating that this cellular protein may be involved in virus entry/
uncoating or assembly/budding steps.
To determine if virus entry and uncoating steps are affected by
depletion of hnRNP K, we used a recombinant virus (VSV-PLuc)
which encodes a P-luciferase (P-Luc) fusion protein, in which the
entire coding region of luciferase is fused in frame following
amino acid 196 of the P protein. The VSV-PLuc virus is similar to
VSV-PeGFP described previously (35) and incorporates P-Luc
within virus particles. Luciferase activity can be readily detected in
extracellular virions and in infected cells (data not shown). Cells
transfected with NT or hnRNP K siRNA were infected with VSVPLuc at an MOI of 300 to allow readily detectable levels of luciferase. Following virus adsorption on ice, cells were washed, and
luciferase activity was determined in extracts of cells at 0, 0.5, 1,
and 1.5 h postincubation at 37°C to enable virus entry and uncoating. Results (Fig. 2D) show that luciferase activity in these cells was
not significantly affected in the presence or absence of hnRNP K,
indicating that this protein does not play any discernible role in
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virus entry and uncoating steps. Furthermore, using a low MOI
(0.01), a multicycle virus growth condition, we observed that the
percentage of cells infected with wt VSV increased with time in
the presence of hnRNP K, while in cells depleted of hnRNP K, the
relative percentage of infected cells remained low, reaching up to
about 15% of that of NT siRNA-treated cells at 16 hpi (Fig. 2E).
On the other hand, we found no differences in the percent infection when these cells were infected with the budding-incompetent
VSV⌬G (Fig. 2E). Taken together, the results suggest that hnRNP
K is required for virus egress in infected cells and that its depletion
may negatively affect assembly and/or release of virus required for
further rounds of infection.
hnRNP K alters the expression of TIA1, a known negative
regulator of VSV replication. Since hnRNP K is known to influence expression of many cellular genes, we wondered whether its
depletion alters expression of cellular genes that have been shown
to be involved in VSV replication. Previous studies from our laboratory showed that PCBP2 and PCBP1 as well as TIA1 inhibit
VSV replication (29, 30). Thus, we examined the levels of these
proteins in cells depleted of hnRNP K by siRNA transfection. Figure 3A shows that knockdown of hnRNP K had no measurable
effect on the levels of PCBP1/2. Expression levels of another cellular protein, NF90, which is known to inhibit replication of several other viruses such as HIV-1 (38), Ebola virus (39), and influenza virus (40), was also not affected by hnRNP K depletion (Fig.
3A). Interestingly, under this condition, we observed a reproducibly greater than 2-fold increase in the total amount of TIA1 protein (Fig. 3B and C). Strikingly, hnRNP K depletion resulted in a
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FIG 4 hnRNP K is required for survival of VSV-infected cells. (A) Knockdown of hnRNP K reduces cell survival during VSV infection. HeLa cells were
transfected with NT or hnRNP K siRNA at concentration of 10 nM for 60 h. Cells were mock infected or infected with VSV at an MOI of 0.01. At 6, 12, and 18
hpi, cell survival was determined by a CellTiter-Glo Kit. The percentage of cell viability in NT siRNA-transfected and mock-infected culture at the beginning of
infection was set at 100%. Data from three independent experiments are shown with error bars representing the standard errors of means. **, P ⬍ 0.01; NS,
nonsignificant. (B) Caspase 3 activation is more pronounced in infected cells lacking hnRNP K. The experiment was conducted as described in panel A. Infected
cells were lysed and analyzed at the indicated time points to detect procaspase 3, activated caspase 3 (p17), hnRNP K, and VSV M protein using specific antibodies.
Actin served as a loading control. (C) Quantification of p17 protein levels (arbitrary units) from three independent experiments as described in panel B. The level
of activated caspase 3 (p17) in cells treated with siRNA targeting hnRNP K at 18 hpi was set arbitrarily at 1, and the relative levels of p17 in other samples were
then determined. Error bars represent the standard errors of means from three independent experiments. ***, ⬍ 0.001; **, P ⬍ 0.01. (D) wt MEF or TIA1⫺/⫺ MEF
cells were transfected with NT or hnRNP K siRNA at a concentration of 20 nM for 60 h. Cells were mock infected (mock) or infected with VSV at an MOI of 1.
At 4 and 8 hpi, cells were lysed and subjected to WB with the indicated antibodies. (E) Quantification of p17 levels (arbitrary units) from three independent
experiments, with error bars representing the standard errors of means. The level of p17 in wt MEFs treated with siRNA targeting hnRNP K was set arbitrarily at
1, and the relative levels of p17 in other samples were then determined. ***, P ⬍ 0.001.

dramatic shift in the ratio of the two isoforms (TIA1a and TIA1b)
of the protein (Fig. 3B and D). In mock-treated or NT siRNAtreated cells, the amount of TIA1b was approximately 12% of
TIA1a, whereas in hnRNP K-depleted cells, TIA1b was detected at
significantly higher levels (about 3-fold) than TIA1a (Fig. 3B).
These results were observed when individual siRNAs specific for
hnRNP K or pooled siRNAs were used (Fig. 3B), indicating that
the effect of hnRNP K protein on altered expression of TIA1 isoforms was not due to off-target effects. The altered expression of
the two isoforms was detected at the mRNA level (Fig. 3E), indicating that hnRNP K regulates the expression of these two isoforms at the transcription and/or splicing level. Similar results
were also obtained in HEK293 cells (data not shown) and wt MEFs
(see Fig. 4D).
Since depletion of hnRNP K led to increased levels of the
TIA1b isoform and inhibition of virus replication, we examined
whether TIA1b inhibits VSV replication, as was demonstrated for
the TIA1a isoform previously (30). In VSV-infected cells overexpressing HA-tagged TIA1b, the viral M protein levels were reduced (Fig. 3F). The reduction in M protein levels was observed in
TIA1b-expressing cells infected with VSV (Fig. 3F, lanes 1 to 3) or
VSV⌬G (lanes 4 to 6) or in NC-transfected cells (lanes 7 to 9),
suggesting that TIA1b inhibits VSV replication. Thus, it appears
that hnRNP K depletion results in increased accumulation of
TIA1b, which is also responsible for inhibition of VSV replication.
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hnRNP K is required for survival of VSV-infected cells. hnRNP K plays essential roles in cell survival. Its cleavage by different
granzymes initiates cell death processes, and its depletion primes
the cells to undergo programmed cell death under various apoptotic stimuli (9, 13, 41, 42). While performing our studies, we
observed that VSV-infected cells depleted of hnRNP K exhibited
enhanced cytopathic effects and cell death compared to the infected cells not depleted of the protein. Therefore, we examined if
hnRNP K plays any role in cell survival during VSV infection.
Depletion of hnRNP K did not affect the viability of mock-infected cells significantly; however, the viability of VSV-infected
cells was significantly reduced with time postinfection (Fig. 4A).
The results show that viability of VSV-infected cells depleted of
hnRNP K was reduced to approximately 63% and 25% at 12 and
18 hpi, respectively, whereas the viability of NT siRNA-treated
cells infected with VSV was reduced only to 92% and 60%, respectively, at the corresponding times postinfection (Fig. 4A). Consistent with the increase in cell death, the amount of cleaved caspase
3 (p17) was found to be 7-fold higher in cells lacking hnRNP K at
12 hpi (Fig. 4B and C).
Since TIA1 is a proapoptotic protein (43, 44), we wondered if
the upregulation of TIA1 in hnRNP-depleted cells is responsible
for the enhanced apoptosis observed in these cells infected with
VSV. To this end, we examined the apoptosis occurring in wt and
TIA1⫺/⫺ MEFs (34) when hnRNP K is silenced by siRNA and
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FIG 5 VSV-mediated cell death in hnRNP K-depleted cells is associated with increased levels of proapoptotic proteins Bcl-XS and Bik. (A) HeLa or HEK293 cells
transfected with siRNAs for 60 h were infected with VSV at an MOI of 1 for 6 h. The levels of proapoptotic proteins Bak, Bad, Noxa, and antiapoptotic factor FLIP
were detected by WB using specific antibodies. (B and C) mRNA levels of proapoptotic proteins (B) or antiapoptotic proteins (C) in hnRNP K-depleted HeLa
cells infected with VSV. siRNA treatment and virus infections were performed as described in panel A. Total RNA was converted to cDNA using oligo(dT)
primers followed by PCR with specific primers. The mRNA level of cellular ribosomal protein L32 was used as an internal control. A DNA ladder (bp) is shown
on the right. Values at the top or bottom of the lanes represent relative levels of mRNAs, using levels in the NT lane as 1. The Bcl-XS level is relative to the Bcl-XL
level in the NT lane. The asterisk indicates the DNA product of an undocumented isoform of Bag1 or a nonspecific product. (D) mRNA levels of antiapoptotic
or proapoptotic proteins in hnRNP K-depleted HEK293 cells infected with VSV. siRNA treatment, virus infection, and mRNA detection were as described above.

subsequently infected with VSV. Results (Fig. 4D and E) show that
activation of caspase 3 (as measured by the levels of p17) occurred
to similar extents in VSV-infected wt and TIA1⫺/⫺ MEFs depleted
of hnRNP K, indicating that VSV-induced cell death in hnRNP
K-depleted cells is independent of TIA1.
VSV-mediated cell death in hnRNP K-depleted cells is associated with increased levels of proapoptotic proteins and decreased levels of antiapoptotic proteins. VSV infection upregulates the expression of proapoptotic proteins such as Noxa and
Bak that are involved in virus-mediated apoptosis in cell culture
(45–47). On the other hand, hnRNP K is known to support the
expression of antiapoptotic proteins such as the caspase inhibitor
protein XIAP (X-linked inhibitor of apoptosis protein) (12),
FLICE-inhibitory protein (FLIP) (9), and Bcl-XL but suppresses
the expression of proapoptotic Bcl-XS (42). Therefore, we examined if depletion of hnRNP K affects the expression of anti- and/or
proapoptotic proteins that may result in altered survival of VSVinfected cells. Our results show that the levels of Noxa, Bad, and
FLIP were unchanged while the expression of Bak decreased in
both HeLa and HEK293 cells depleted of hnRNP K and infected
with VSV (Fig. 5A). Through semiquantitative RT-PCR, we found
that the mRNA levels of proapoptotic factors Bax and Bid were not
altered significantly in the absence of hnRNP K, whereas the level
of another proapoptotic factor, Bik, was upregulated over 4-fold
(Fig. 5B). The mRNA levels of antiapoptotic factors Bag1 and
Bcl-2A1 but not Bcl-W or XIAP under similar experimental conditions were slightly reduced, whereas the level of Bcl-2 was downregulated greater than 3-fold (Fig. 5C).
A previous study reported that depletion of hnRNP K by
siRNA treatment led to a significant decrease in the level of mRNA
for the antiapoptotic protein Bcl-XL and an increase in the proapoptotic Bcl-XS mRNAs in PC-3 cells as well as several other cell
lines, but no significant differences were observed in HeLa cells
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(42), which was suggested to be due to less efficient depletion of
the protein in this cell line. Therefore, it was of interest to examine
the mRNA levels of Bcl-XL and Bcl-XS in HeLa cells depleted of
greater than 90% of hnRNP K using the pool of four siRNAs
described in our studies above (Fig. 1A). Results from such an
experiment show (Fig. 5B) that the mRNA levels of Bcl-XL and
Bcl-XS remained unchanged in VSV-infected HeLa cells depleted
of hnRNP K compared to levels in the infected cells not depleted of
the protein. In contrast to the results in HeLa cells, we observed a
significant decrease of Bcl-XL and a concomitant increase in
Bcl-XS mRNA levels in HEK293 cells under similar experimental
conditions (Fig. 5D). Interestingly, the level of Bik mRNA was also
reduced significantly (Fig. 5D). These results indicate that the
VSV-mediated apoptosis in hnRNP K-depleted cells is associated
with alterations in the balance of pro-/antiapoptotic Bcl-2 proteins (decrease of antiapoptotic proteins such as Bcl-XL, Bag1, and
Bcl-2 and an increase of proapoptotic factors including Bcl-XS and
Bik) though the identity of these proteins might differ in different
cell lines.
hnRNP K maintains expression of cellular proteins required
for VSV infection. Since hnRNP K is involved in regulating expression of many cellular genes (1), it is possible that depletion of
hnRNP K might influence levels of cellular proteins that are
known to be required for VSV replication, leading to inhibition of
virus replication. Recently, we reported through a genome-wide
siRNA screen the requirement of several host factors for VSV replication at various stages of the virus infection cycle (33). Among
these, alanine deaminase-like (ADAL) protein was shown to be
required for the VSV assembly/budding step, whereas GBF1,
ARF1, and the proteins of the coatomer I (COPI) complex were
required for VSV genome transcription and replication (33, 48).
Therefore, we examined if hnRNP K silencing affects the expression of some of these cellular factors. Results show that hnRNP K
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FIG 6 hnRNP K regulates expression of cellular proteins required for VSV infection. (A and B) HeLa cells transfected with siRNA for 60 h were infected with VSV
at an MOI of 0.01 for 12 h. The levels of the proteins were detected by WB using specific antibodies. (C) Quantification of ADAL and ARF1 protein levels
(arbitrary units) from three independent experiments, with error bars showing the standard errors of means. The level of ADAL or ARF1 in the NT lane was
arbitrarily set at 1. **, P ⬍ 0.01. (D) Involvement of hnRNP K in regulating expression of cellular proteins that affect VSV infection. hnRNP K inhibits TIA1a/b
expression, which is known to inhibit VSV replication. Increased levels of antiapoptotic proteins such as Bcl-XL, Bag1, and Bcl-2 and/or reduction in the levels
of apoptotic proteins Bcl-XS and Bik promotes cell survival for increased VSV replication, while maintenance of factors such as ADAL and ARF1 is required for
VSV replication.

depletion by siRNA did not alter the levels of COPI proteins such
as COPB1 and COPZ or GBF1 (Fig. 6A). Furthermore, under the
same conditions, the level of GS28, a putative protein of the cisGolgi compartment that is involved in endoplasmic reticulum
(ER)-Golgi transport (49) and apoptosis (50, 51), was not affected
either (Fig. 6A). On the other hand, depletion of hnRNP K resulted in a 3- to 4-fold reduction in the levels of ARF1 and ADAL
proteins (Fig. 6B and C). These results suggest that hnRNP K
regulates expression of certain cellular proteins required for VSV
replication.
DISCUSSION

hnRNP K is a multifunctional protein in the subfamily of hnRNPs
which carry three KH domains and is involved in gene expression
and mRNA metabolism. Previously, our genome-wide screening
study identified hnRNP K as a factor required for VSV infection
(33). In this communication, we conducted further studies to decipher the role of hnRNP K in supporting VSV infection. Our
results reveal that hnRNP K primarily supports VSV infection at
the level of virus propagation, but it is also involved in viral replication and transcription to some extent (Fig. 1 and 2). Further
studies showed that hnRNP K is required for suppressing apoptosis induction and promoting survival of infected cells, which in
turn supports VSV growth. We found that hnRNP K helps maintain the low levels of expression of proapoptotic proteins such as
BiK and Bcl-XS and the high levels of expression of antiapoptotic
proteins such as Bcl-XL, Bag1, and Bcl-2. In addition to the role of
hnRNP K in cell death suppression, our study found that hnRNP
K supports expression of several cellular factors required for VSV
replication and downregulates expression of some of the cellular
factors known to inhibit VSV replication. Thus, the studies presented here reveal critical roles of hnRNP K in VSV infection
through multiple mechanisms. The supportive role of hnRNP K
in VSV infection is observed in all cell lines examined in this study,

10066

jvi.asm.org

whereas its role in suppression of apoptosis is mediated by a balance between several pro- and antiapoptotic factors and is cell type
dependent.
hnRNP K is reported to play diverse roles in many virus infections. Its interactions with viral components and/or cellular factors support the replication of viruses, including enterovirus 71,
Sindbis virus, dengue virus, chikungunya virus, hepatitis C virus,
HBV, HIV-1, HSV-1, African swine fever virus, human cytomegalovirus, and Epstein-Barr virus (16, 18–28). Interestingly, in human cytomegalovirus-infected cells, hnRNP K is essential for virus replication as it promotes the viability of infected cells (28).
Although our studies reveal such a role for hnRNP K in VSV
replication, it may also be involved in virus assembly and/or release. So, how then does hnRNP K facilitate VSV assembly and/or
release from infected cells? The answer to this critical question
requires further investigation, including examination of interactions of viral proteins with hnRNP K. It is possible that hnRNP K
may directly or indirectly interact with the viral components to
mediate virus assembly or egress. Since hnRNP K is known to be
involved in cellular gene expression and signal transduction (3), it
is also possible that it modulates expression of certain cellular
proteins that are important for VSV egress, such as ADAL (Fig. 6B
and C), which was shown before to be required for VSV assembly
and budding (33). Alternatively, hnRNP K may recruit factors
necessary for virus egress through its K protein-interacting (KI)
domain.
Although interaction of VSV proteins with hnRNP K is being
examined currently, one required role for hnRNP K in VSV infection is found to be at the level of maintaining the viability of
infected cells. VSV-infected cells exhibited significantly reduced
cytopathic effects and did not undergo apoptosis as fast in the
presence of hnRNP K as in cells lacking this protein. Thus, hnRNP
K suppresses VSV-induced apoptosis. Examination of the levels of
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several factors involved in apoptosis suggested that increased
apoptosis of VSV-infected cells lacking hnRNP K does not involve
Noxa and Bak, two proapoptotic proteins previously shown to
mediate VSV-induced cell death (45–47). Rather, significantly increased levels of Bik or Bcl-XS appear to regulate apoptosis in
hnRNP K-depleted cells by regulating the balance of the pro-/
antiapoptotic Bcl-2 proteins. In HeLa cells, the levels of Bcl-XS
remained unchanged in the presence or absence of hnRNP K, but
Bik was upregulated over 4-fold, which presumably was responsible for increased cell death. In contrast, in HEK293 cells, Bcl-XS
levels were increased significantly in the absence of hnRNP K
along with decreased levels of Bcl-XL while the level of Bik was
significantly reduced, suggesting that in this cell type, the decrease
in the Bcl-XL/Bcl-XS ratio may primarily regulate apoptosis of
VSV-infected cells. Thus, it appears that hnRNP K regulates the
balance between pro- and antiapoptotic factors in a cell-type-dependent manner so as to allow infected cells to survive longer for
increased virus growth. It should be noted, however, that considering the multiple roles played by hnRNP K in many cellular processes, it is possible that suppression of apoptosis may not be solely
responsible for increased growth of VSV in infected cells. Further
studies would have to be conducted to delineate additional roles of
hnRNP K, if any, in supporting VSV growth.
hnRNP K is known to function closely with p53, a well-known
mediator of apoptosis, at multiple levels to coregulate cell fate.
Together with p53, hnRNP K binds to promoters to upregulate a
number of genes encoding DNA damage response factors (52),
and in combination with large intergenic noncoding RNA p21
(lincRNA-p21), it regulates global gene repression downstream of
a p53-mediated response (53). Evidence also suggests that hnRNP
K acts as a cell survival enhancer independent of p53 by maintaining a high level of antiapoptotic proteins, including FLIP and
XIAP (9, 12). Studies presented here reveal that the role of hnRNP
K in survival of VSV-infected cells is independent of its interaction
with p53. This interpretation is consistent with the observations
that VSV-induced apoptosis in the absence of hnRNP K occurs
with similar kinetics in both p53-inactive cells (HeLa and
HEK293) and wild-type p53-active cells such as MCF-7 and MEF
cells. Additionally, apoptosis induced by other factors such as cycloheximide treatment or other virus infections (lymphocytic
choriomeningitis virus [LCMV] and human parainfluenza virus
type 3 [HPIV3]) was also enhanced in hnRNP K-depleted cells
(data not shown). These observations highlight the essential role
of hnRNP K independent of p53 in protecting cells from apoptosis
triggered by different stimuli.
VSV is being used as an oncolytic agent for various types of
tumors (55–58). One of the hallmark features of most cancer cells
is the defective type I interferon response and signaling (59),
which allows viruses such as VSV to grow rapidly and kill the cells.
hnRNP K is upregulated in many types of cancerous cells (10, 11,
60) and is considered a prognostic marker and a target for tumor
therapy (11, 61). The results showing that hnRNP K supports VSV
propagation further add to the understanding of why tumors provide an appropriate microenvironment for VSV growth.
Our studies also reveal a novel role of hnRNP K in suppressing
not only the expression of the TIA1b isoform (a differentially
spliced isoform of TIA1a) but also the overall levels of TIA1. The
function of these two isoforms in cells is poorly understood, except that TIA1b displays greater splicing-stimulatory activity than
TIA1a (62). Previously, we along with others demonstrated that
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TIA1 inhibited VSV replication (30, 63) although the contribution of the TIA1b isoform was not investigated. Our present results demonstrate that TIA1b is inhibitory to VSV replication.
Since expression of TIA1 is mediated by many cellular factors
including miRNAs (64, 65), it would be of interest to examine how
hnRNP K regulates or is regulated by these factors, which may
provide further understanding of the role of cellular factors involved in VSV replication.
The results presented here do not exclude the involvement of
hnRNP K in supporting VSV assembly and budding. Although
not much is known about the direct role(s) of hnRNP K in lipid
metabolism, in protein trafficking, in the growth of plasma membrane, or in secretory pathways, which are directly involved in
virus assembly and budding, hnRNP K regulates the expression of
15-lipoxygenase, a key enzyme in the metabolism of phospholipids and internal membrane (66). Studies of the hnRNP K interactome revealed more than 100 interacting partners and determined
that hnRNP K protein is present in the nucleus, cytoplasm, mitochondria, and the vicinity of the plasma membrane (31). Thus, it
is possible that hnRNP K exerts its positive impact on VSV growth
through one or more of its interacting partners.
In summary, we demonstrate here a role(s) of hnRNP K in VSV
infection (Fig. 6D). The mechanisms by which hnRNP K promotes VSV infection involve the following: (i) promoting cell survival via suppression of proapoptotic proteins (Bik and Bcl-XS)
and upregulation of antiapoptotic proteins (Bcl-XL, Bag1, and
Bcl-2); (ii) suppression of expression of VSV-inhibitory protein
TIA1; and (iii) upregulation of cellular factors favoring VSV infection such as ARF1 and ADAL. Our data also provide a better
understanding of why tumor cells provide a more conducive environment for VSV replication. Overall, our studies presented
here suggest a multifunctional role of hnRNP K in VSV infection
and prompt us to undertake additional research to uncover its
involvement in virus-host interactions.
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